---
document_datetime: 2025-01-21 12:31:50
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/alofisel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: alofisel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.6292799
conversion_datetime: 2025-12-21 20:00:53.61167
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Alofisel

Procedural steps taken and scientific information after the authorisation

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                     | Opinion/ Notification 1 issued on Product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0049/G            | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its 01/07/2024 |                                             | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal Product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   | Product no longer authorised   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| IB/0050/G | manufacturing sites This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 07/05/2024                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                     | longer            | authorised                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------|
| PSUSA/10676 /202309 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/04/2024 n/a    | PRAC Recommendation - maintenance |
| II/0047/G           | This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites Medicinal Product | 25/01/2024 n/a no |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0046   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/09/2023 | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0044/G | This was an application for a group of variations. Grouped application comprising one type II variation and two type IB as follows: - Update of section 4.8 of the SmPC in order to update the Summary of the safety profile and to add anal abscess, proctalgia and anal fistula to the list of adverse drug reactions on post-marketing experience following the assessment of R/0036 based on a review of the MAH's Global Safety Database. - Update of section 4.2 of the SmPC in order to add the term Perilesional as an EDQM term, following the assessment of R/0036. - Update of sections 1, 2.2, 3, 4.2, 6.5 and 6.6 of the SmPC in order to replace the term 'suspension for injection' for 'dispersion for injection', following the assessment of R/0036. The Annex A, Package Leaflet and Labelling are updated in accordance. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Medicinal Product | 14/09/2023 | 05/04/2024 no | SmPC, Labelling and PL This was a grouped application comprising of one type II variation and two type IB. It introduced the update of section 4.8 of the SmPC in order to add anal abscess, proctalgia and anal fistula to the list of adverse drug reactions on post-marketing experience based on a review of the MAH's Global Safety Database. Furthermore, this variation updated section 4.2 of the SmPC and added the term `Perilesional` as an approved EDQM term. Sections 1, 2.2, 3, 4.2, 6.5 and 6.6 of the SmPC were updated in order to replace the term 'suspension for injection' for 'dispersion for injection', following the assessment of R/0036. The Annex A, Package Leaflet and Labelling are updated in accordance. The black triangle sign was removed, since the product doesn't fall under the additional monitoring criteria anymore. For more information, please refer to the Summary of Product Characteristics. longer authorised |

<div style=\"page-break-after: always\"></div>

| II/0045/G           | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product   | 26/04/2023         | 05/04/2024    | Annex II                         | Annex II have been updated as follows: The following site is included under manufacturer of the biological active substance: Takeda Ireland Ltd., Grange Castle Business Park, Dublin 22, D22 XR57, Ireland authorised                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10676 /202209 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                                                                                                                                         | 14/04/2023         | n/a longer    |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| R/0036              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                             | 10/11/2022 Product | 10/01/2023 no | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CAT and CHMP considered that the benefit-risk balance of Alofisel in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The MAH updated the RMP with the status of the ongoing Cx601 0303 study. Annex A of Alofisel was updated in order to reflect correct QRD terminology. The product information was updated in accordance with the latest QRD template and minor wording clarifications have also been included. Further, the MAH will update section 4.8 of the SmPC in a separate procedure. |
| IB/0042/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Medicinal                                                                                                                                                                                                                                                   | 16/12/2022         | n/a           |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                              |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| IB/0039/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.z - Quality change - Active substance - Other variation Product no | 07/11/2022 |
| IB/0041/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 03/10/2022 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place             |            |                       | authorised                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|-----------------------------------|
| IB/0040/G           | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.z - Quality change - Finished product - Other variation | 15/09/2022 | n/a                   |                                   |
| IB/0038             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                             | 14/07/2022 | n/a Product no longer |                                   |
| IB/0037             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                     |            | 27/06/2022 n/a        |                                   |
| IB/0033             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation Medicinal                                                                                                                                           | 19/04/2022 | n/a                   |                                   |
| PSUSA/10676 /202109 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                              | 07/04/2022 | n/a                   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0034/G   | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation   | 31/03/2022   | n/a        | longer authorised                                                                                                                                                                                                                                                       |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure Product                                                                                           | 04/03/2022   | n/a no     |                                                                                                                                                                                                                                                                         |
| IB/0032     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                                                                                                                                                                                                                                                                                                                          | 04/03/2022   | 10/01/2023 | Annex II To extend the due date for the Long Term Extension Study Cx601-0303 (ADMIRE-CD II Study) from 2Q/3Q 2022 to Q1/Q2 2024 in both the RMP and in the product information Annex II, as the enrolment has been significantly affected due to the COVID-19 pandemic. |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                      |            |            |                 | In addition the MAH has taken the opportunity to bring the annexes in line with QRD template (vers.10.2).   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------|
| IB/0028/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 23/02/2022 | n/a        | longer          | authorised                                                                                                  |
| IB/0031             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                          | 02/02/2022 | n/a no     |                 |                                                                                                             |
| PSUSA/10676 /202103 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                          | 28/10/2021 | n/a        |                 | PRAC Recommendation - maintenance                                                                           |
| II/0027             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method Product       | 16/09/2021 | n/a        |                 |                                                                                                             |
| IB/0025             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product Medicinal                                                                                                                               | 21/06/2021 | 22/10/2021 | Annex II and PL |                                                                                                             |
| PSUSA/10676         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                        | 09/04/2021 | n/a        |                 | PRAC Recommendation - maintenance                                                                           |

<div style=\"page-break-after: always\"></div>

| /202009             | darvadstrocel                                                                                                                                                                                                                                                                                            |                    |               |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------|-----------------------------------|
| IA/0024             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                            | 03/03/2021         | n/a           |                        |                                   |
| II/0021             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                   | 28/01/2021         | n/a           |                        | authorised                        |
| IB/0023/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 27/01/2021         | n/a           | longer                 |                                   |
| IAIN/0020/G         | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                              | 30/11/2020 Product | 22/10/2021 no | SmPC, Labelling and PL |                                   |
| PSUSA/10676 /202003 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                              | 29/10/2020         | n/a           |                        | PRAC Recommendation - maintenance |
| IB/0019             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS Medicinal                                                                                                                                                                               | 19/10/2020         | 22/10/2021    | SmPC and PL            |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                        | 28/07/2020                   | n/a        | IB/0018                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|------------|-------------------------------|
| II/0016/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.1.z - Change in the specification parameters | 28/05/2020                   | n/a longer | and/or limits of the finished |
| /201909   | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/04/2020                   | n/a        | PSUSA/10676                   |
| IB/0015   | product - Other B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                | variation 19/03/2020 Product | n/a no     |                               |
| II/0010/G | This was an application for a group of variations. B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.II.g.2 - Introduction of a post approval change Medicinal                                                                                                                                                                                                                                                                                       | 27/02/2020                   | n/a        |                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                            |                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| II/0009   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                               | 27/02/2020 n/a authorised                                     |
| IA/0014   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                 | 24/01/2020 27/03/2020 SmPC, Annex II, Labelling and PL longer |
| IB/0012/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate Product | 19/12/2019 n/a no                                             |
| IB/0008/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.5 - Stability of FP - Extension of the shelf Medicinal                                                                                                                                    | 07/10/2019 27/03/2020 SmPC                                    |

<div style=\"page-break-after: always\"></div>

|                     | life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10676 /201903 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/10/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0006             | Submission of an updated RMP version 7 in order to propose replacement of the observational PASS study (Category 3) with two separate studies: a long-term safety extension of the ADMIRE-CD II study and a retreatment PASS. The European multi- database linkage study is added for the assessment of the potential risk of tumorgenicity. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Product | 29/05/2019 | n/a no     | longer                 | Following EMA scientific advice this variation was to update the post authorisation follow up on effectiveness and safety as outlined in the RMP in order to more effectively assess long-term effectiveness and safety of darvastocel including repeat administration. The Pharmacovigilance plan was updated and Protocol synopses and on a 4 year extension of the ADMIRE II study, a dedicated re-treatment PASS and a European multi-database linkage study were agreed to replace the previously agreed re-treatment PASS. |
| PSUSA/10676 /201809 | Periodic Safety Update EU Single assessment - darvadstrocel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/04/2019 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0005             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/04/2019 | 27/03/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0002     | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/08/2018   | n/a                  |                        |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------|------------------------|
| IAIN/0003/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 12/07/2018   | n/a                  | authorised             |
| T/0001      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/04/2018   | 08/05/2018 no longer | SmPC, Labelling and PL |

Medicinal Product no longer authorised